Genmab — Marts 2023
-
The M&A hunt is on — here are the prime targets
Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.
PharmaVoice (www.pharmavoice.com)
-
Tror ikke lige Amanda er så heldig med den "liste" over opkøbs kandidater. Altimmune har lige præsenteret data. Fint vægtab på ca 10%. Men "Most patients experienced nausea and vomiting of mild and moderate severity"
-
Ja, AbbVie (ABBV) står over for et af de stejleste patentfrafald i branchen, når Humira mister sin amerikanske eksklusivitet næste år. Analytikere forventer, at virksomheden vil have 69 milliarder dollars i frit cash flow frem til 2024 for at genopbygge sine hylder. Andre firmaer, der forventes at se høje kontanter, er Roche, Bristol Myers og Merck.
-
-
Daratumumab Seen as Effective in Patients With Refractory Acquired Hemophilia A https://www.rarediseaseadvisor.com/news/hem-news-briefs/daratumumab-effective-refractory-acquired-hemophilia-a-immunosuppressants-fviii/
-
Godmorgen
-
March 29, 2023 : Annual General Meeting 2023 https://www.proinvestor.com/investornyt/960870/march-29-2023-annual-general-meeting-2023
-
Bank of America Securities analyst Sachin Jain maintained a Buy rating on Genmab (GMAB – Research Report) yesterday and set a price target of $48.00. https://markets.businessinsider.com/news/stocks/bank-of-america-securities-reaffirms-their-buy-rating-on-genmab-gmab-1032196485
or it's my clumsy fingers. 3,300 yesHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind